Travelers With Cutaneous Leishmaniasis Cured Without Systemic Therapy by Morizot, G. et al.
M A J O R A R T I C L E
Travelers With Cutaneous Leishmaniasis Cured
Without Systemic Therapy
G. Morizot,1 E. Kendjo,2 O. Mouri,2 M. Thellier,2 A. Pérignon,3 F. Foulet,5 F. Cordoliani,6 E. Bourrat,6,7 E. Lafﬁtte,8 I. Alcaraz,9
N. Bodak,10 C. Ravel,4 M. Vray,11 M. Grogl,12 D. Mazier,2 E. Caumes,3 L. Lachaud,4 P. A. Buffet,1,2,13 and the Cutaneous
Leishmaniasis French Study Groupa
1Unité d’Immunologie Moléculaire des Parasites, Institut Pasteur de Paris, 2Service de Parasitologie-Mycologie and 3 Service de Maladies Infectieuses et
Tropicales, Hôpital Pitié-Salpêtrière, Paris, 4 French Reference Centre on Leishmaniasis, Montpellier, 5Service de Parasitologie-Mycologie, Hôpital Henri
Mondor, Créteil, 6Service de Dermatologie, Hôpital Saint-Louis, Paris, and 7Service de Pédiatrie générale, Hôpital Robert Debré, Paris, France; 8Clinique
de Dermatologie, Hôpitaux Universitaires de Genève, Switzerland; 9Service de Maladies Infectieuses et Pathologie du voyageur, Hôpital Gustave Dron,
Tourcoing, 10Service de Dermatologie, Hôpital Necker, Paris, 11Unité de Recherche et d’Expertise Épidémiologie des Maladies Émergentes, Institut
Pasteur de Paris/INSERM, France; 12Walter Reed Army Institute of Research, Silver Spring, Maryland; and 13UMRs 945 INSERM–Paris 6 University,
France
(See the Editorial Commentary by Bailey on pages 381–3.)
Background. Cutaneous leishmaniasis (CL) is a disﬁguring but not life-threatening disease. Because antileish-
manial drugs are potentially toxic, the World Health Organization (WHO) recommends simple wound care or local
therapy as ﬁrst-line treatment, followed or replaced by systemic therapy if local therapy fails or cannot be per-
formed.
Methods. To determine the feasibility and impact of the recommended approach, we analyzed the results of a
centralized referral treatment program in 135 patients with parasitologically proven CL.
Results. Infections involved 10 Leishmania species and were contracted in 29 different countries. Eighty-four of
135 patients (62%) were initially treated without systemic therapy. Of 109 patients with evaluable charts, 23 of 25
(92%) treated with simple wound care and 37 of 47 (79%) treated with local antileishmanial therapy were cured by
days 42–60. In 37 patients with large or complex lesions, or preexisting morbidities, or who had not been cured with
local therapy, the cure rate with systemic antileishmanial agents was 60%. Systemic adverse events were observed in
15 patients, all receiving systemic therapy.
Conclusions. In this population of CL patients displaying variable degrees of complexity and severity, almost
two-thirds of patients could be initially managed without systemic therapy. Of these, 60 were cured before day 60.
The WHO-recommended stepwise approach favoring initial local therapy therefore resulted in at least 44% of
all patients being cured without exposure to the risk of systemic adverse events. Efforts are needed to further simpli-
fy local therapy of CL and to improve the management of patients with complex lesions and/or preexisting
comorbidities.
Keywords. cutaneous leishmaniasis; systemic antimony; intralesional antimony; liposomal amphotericin B;
miltefosine.
Typically, cutaneous leishmaniasis (CL) presents as 1
or several chronic, inﬁltrated lesions on exposed parts
of the body [1]. CL lesions are not spontaneously
painful, but they do result in marked local discomfort
when ulcerated or infected with bacteria [2]. In immu-
nocompetent subjects, wide dissemination of CL is un-
common and visceral spread causing pathology is
exceptional [1]. Most if not all published reports of
death in patients with CL are related to systemic therapy,
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sometimes with a toxic drug lot [3–6]. Systemic administration of
reference agents such as pentavalent antimony, pentamidine, for-
mulations of amphotericin B, or oral miltefosine can indeed cause
systemic toxicity [3, 5, 7–13]. International and national treat-
ment guidelines for CL thus favor options that increase the like-
lihood of rapid healing of CL lesions with the smallest risk of
severe adverse events [14–16]. Unspeciﬁc wound care followed
by patience, a cheap treatment devoid of toxicity, has been rec-
ommended [15, 16], but the proportion of patients who can ac-
tually beneﬁt from it has not been determined and may be low.
Spontaneous healing rates in patients with CL are indeed
highly variable (0%–71%, [17]) and furthermore inﬂuenced by
the infecting species. Simple wound care is not an optimal
option in patients with disﬁguring lesions [14–16]. The imple-
mentation of local antileishmanial therapy is logistically de-
manding and dependent on lesion topography. For example,
the local therapy currently recommended in France requires
the sequential application of cryotherapy and intralesional
injections of antimony (Cryo + IlSb). The procedure is highly ef-
fective [18–20] but is relatively painful and difﬁcult to apply to
“complex” lesions (ie, those located on the ears, eyelids, or lips,
or those close to small joints). Additionally, it can only be per-
formed by trained physicians who have access to liquid nitrogen.
Not least, no systemic therapeutic option is effective and ap-
plicable in all forms of CL [21]. Although high-dose oral ﬂu-
conazole was effective in Iran [22] and Brazil [23], observance
and cost may limit its impact. Miltefosine has been equivalent [24]
or superior [25] to systemic Glucantime in some settings, but
its teratogenicity and long half-life are issues for wide-scale use.
Considering the limitations of the different options and the
variable severity of CL, recent guidelines recommend using
wound care without antileishmanial therapy whenever possible,
then local therapy whenever possible, and ﬁnally systemic therapy
if local therapy fails or cannot be performed (Figure 1) [15, 16].
This stepwise process is intended to limit the risk of severe
adverse events and reduce costs while preserving efﬁcacy. It
Figure 1. Stepwise treatment approach in cutaneous leishmaniasis. Summary of recent French recommendations for the therapy of cutaneous leishman-
iasis [27], expressed as a treatment algorithm. This algorithm was used by the French leishmaniasis reference center experts involved in the centralized re-
ferral treatment program. Abbreviations: L-AmB, liposomal amphotericin B; Sb, pentavalent antimony.
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integrates many parameters, including the size, aspect, topogra-
phy, and number of lesions, the suspected or proven infecting
species, and the patient’s age and general health status
(Figure 1) [26]. These treatment guidelines are based on clinical
experience and analyses of published data [16, 27] but have not
been evaluated in clinical practice.
In the present report, we analyzed data collected by experts
with the French leishmaniasis reference center (NRCL); these
experts provide treatment advice to physicians attending pa-
tients with leishmaniasis. Data regarding 135 consecutive CL
patients over 6 years were captured and used to determine the
applicability of the recommended approach. Speciﬁcally, we
focused on determining—in the general population of CL
patients—the proportion of patients who could be treated
without systemic therapy, and the proportion of positive
outcome in each treatment category (ie, simple wound care,
local therapy, and systemic therapy).
MATERIALS ANDMETHODS
Patients, Medical Care, and Data Collection
From 2006 through 2011, data were collected each time treat-
ment advice was sought from an expert at the NRCL. Data
from patients with parasitologically conﬁrmed tegumentary
leishmaniasis were collected. Diagnostic procedures were not
modiﬁed by the process, expert treatment advice was part of
normal medical care, and data collection was in the context of
national health surveillance. Patients were informed of the
process by their attending physician using a procedure common
to all French National Reference Centers (http://www.parasitologie.
univ-montp1.fr/conseil.htm) and gave their oral consent for data
collection. Mention of this consent was written in the medical
chart.
Parasitological Conﬁrmation of Diagnosis: Species Identiﬁcation
Parasitological diagnosis was performed and analyzed as previ-
ously described [17, 28] by lesion scraping, biopsy, or aspirate
followed by direct examination of Giemsa-stained smears, his-
tological analysis of Hematein-Eosin-Safran- or Giemsa-
stained tissue sections, culture, or polymerase chain reaction
(PCR). Whenever possible, tissue samples and aliquots of posi-
tive cultures were sent to the NRCL for conﬁrmation and
species identiﬁcation using a multilocus sequence typing ap-
proach based on the analysis of 7 single-copy coding DNA se-
quences (C. Ravel, personal data).
Physicians
Attending physicians were general practitioners, dermatolo-
gists, infectious diseases specialists, parasitologists, or pediatri-
cians who were aware of the expert advice available from the
NRCL.
Experts, Guidelines, Formalized Process for Treatment Advice,
and Outcome
Treatment advice to physicians was provided by 2 specialists
(L.L, P.A.B.) with expertise in leishmaniasis therapy [17, 29, 30],
who furthermore participated in the establishment of the French
national guidelines. The availability of the experts was perma-
nent via a mobile phone. Advice was generally provided within
48 hours, most often during the ﬁrst interaction. Guidelines were
initially based on expert reviews published in French [30, 31] or
in English [14, 32, 33]. The content of the published guidelines is
recapitulated as an algorithm in Figure 1; treatment decisions
were made according to this algorithm. The only important
modiﬁcation between 2006 and 2011 was the removal of oral
ﬂuconazole as a ﬁrst-line option for the treatment of Leishman-
ia major CL (at end 2006), when results obtained in French
travelers [17] did not conﬁrm the previous encouraging results
in L. major CL from Saudi Arabia [34]. In the context of the
treatment advice embedded in the national surveillance
program, we optimized data collection as follows. During initial
interactions with attending physicians, information essential
for an accurate therapeutic decision was collected on a stan-
dardized NRCL form by the experts. This included demograph-
ics, travel history, risk factors, medical history, physical
examination including lesion topography, aspect, and size, and
available laboratory parameters. Data from parasitological tests
performed to conﬁrm diagnoses and determine infecting Leish-
mania species were also captured. The infecting Leishmania
species may inﬂuence treatment choice and treatment
outcome; thus, the experts indicated what was the presumptive
infecting species based on epidemiological and clinical data
and used this information to immediately select the treatment
option consistent with guidelines. Six to 8 weeks after the
advice had been provided, the attending physician was contact-
ed by one of the experts and asked to provide complementary
information on species identiﬁcation, treatment actually ad-
ministered, disease outcome (including lesion size and lesion
healing according to a harmonized criterion used in recent
cohort studies and clinical trials [17, 28]), and occurrence of
side effects related to any utilized drugs. The quality of data col-
lection was checked by retrieving available written information
(on medical charts or reports collected during follow-up) to
compare it with all available items in the database.
Database and Data Analysis
The employed database was approved by the French national
commission for information technology rights. Variables were
summarized as frequencies and percentages, means and stan-
dard deviations, or medians and interquartile ranges (IQR), as
appropriate, then compared using the χ2 test when appropriate.
Concordance between suspected and conﬁrmed species was an-
alyzed using the κ statistic. Physicians’ treatment options were
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compared to the expert advice using χ2 tests or Fisher exact test
when appropriate. Statistical analysis was performed using In-
tercooled Stata software, version 10 for Windows. All reported
P values are 2-tailed.
RESULTS
Characteristics of Patients and Lesions
Of 168 patients for whom physicians requested expert advice
from the NRCL, 135 had parasitologically conﬁrmed tegumenta-
ry leishmaniasis. This represents 34% of the 402 patients with CL
reported to the NRCL from metropolitan France during the same
period. The group included 128 patients with localized CL, 5 with
mucosal or mucocutaneous leishmaniasis, 1 with disseminat-
ed cutaneous leishmaniasis, and 1 with post–kala-azar dermal
leishmaniasis. The demographic and clinical characteristics of
patients are summarized in Supplementary Table 1. Twelve
patients (9%) had underlying immunosuppression (1 with
chronic lymphocytic leukemia, 6 with immunosuppressive
therapy, 5 with human immunodeﬁciency virus [HIV] infec-
tion). The duration of disease at the time of diagnosis was ≤36
months, with the exception of 1 patient with HIV coinfection
Figure 2. Total number of patients who acquired the infection in each country (in circles) and geographical distribution of the main Leishmania species
causing cutaneous leishmaniasis in humans in the Old World (upper panel) or in the New World (lower panel; background color as adapted from [35] and
[36]).
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whose lesion had been present for 10 years. CL was contract-
ed in 29 different countries (Figure 2). Old World tegumen-
tary leishmaniasis occurred in 107 patients (79% of all
cases), 90 of whom were travelers and 17 of whom were per-
manent residents in endemic areas for L. infantum in South
Western Europe. New World tegumentary leishmaniasis
(Figure 2) occurred in 28 patients (21% of all cases), 26 of
whom were travelers and 2 of whom lived in endemic areas.
Analysis of lesion topography (Figure 3) showed that 83%
and 89% of lesions were located in body areas where local
injections and application of ointments, respectively, can be
performed.
Characteristics of Physicians Seeking Expert Advice
Ninety physicians asked for advice: 65 used the system once, 25
more than once (range, 2–7); 9% were general practitioners,
51% dermatologists, 19% infectious diseases specialists, 16%
parasitologists, and 5% from other health provider categories.
Parasitological Conﬁrmation and Species Determination
Parasitological diagnosis was conﬁrmed by a single method
(smear, histology, culture, or PCR) in 65 patients (48%) and by
2 or more methods in 70 (52%). The infecting species was iden-
tiﬁed in 70 of the 135 patients (52%). The infecting species pre-
dicted by the expert (based on epidemiological and clinical
data) before formal parasitological identiﬁcation was conﬁrmed
by PCR in patients infected in the Old World in 96% of cases
with a κ of 0.93 (95% CI, 0.92–1.00), and in patients infected in
the New World in 74% of cases with a κ of 0.59 (95% CI, 0.45–
0.82; Supplementary Table 2).
Treatment Outcome
A detailed analysis focused on the main treatment options
(Table 1) was performed on 109 medical charts that contained
outcome data at least at day 42 through day 60. All patients in-
cluded in this detailed analysis had been treated according to
the recommended algorithm (Figure 1). The 26 patients not
Figure 3. Number (%) of lesions per main body area for 262 documented lesions in 135 patients with cutaneous leishmaniasis. Light red areas corre-
spond to lesion locations where performing intralesional injections is particularly painful or potentially harmful but where a topical cream can be applied;
dark red areas correspond to lesion locations where neither intralesional injection nor application of a cream can be performed easily. Based on topogra-
phy, 83% and 89% of lesions can be treated by local injections or application of ointments, respectively.
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included in this detailed analysis had been managed with
options not included in the recommendations (14 patients), or
had received oral ﬂuconazole (when ﬂuconazole was still rec-
ommended as a ﬁrst-line option; 6 patients), or had been lost to
follow-up (6 patients). Twenty-three (92%) of the 25 patients
receiving simple wound care had positive outcomes at days 42–
60. As expected from the algorithm used (Figure 1), none of
these patients had underlying immunodepression and most
were infected with L. major or Leishmania mexicana (84%;
Table 1). The outcome of Cryo + IlSb could be analyzed in 47
patients, 37 of whom (79%) were cured at days 42–60. These
patients were predominantly infected either with L. major or
L. mexicana (29 patients [62%]), or with other Old World
species—Leishmania tropica, Leishmania aethiopica, or L. in-
fantum (16 patients [34%]; Table 1). Four of 19 patients (21%)
with suspected or proven Leishmania braziliensis or Leishman-
ia panamensis/guyanensis infection were treated and cured
without systemic therapy. The outcome after systemic therapy
could be analyzed in 37 patients, 22 of whom (60%) were cured
by days 42–60. In this group, the infecting species was almost
equally distributed between L. major (13 patients [35%]), other
Old World species (9 patients [25%]), and New World species
including L. braziliensis (6 patients [16%]) and L. guyanensis/
L. panamensis (9 patients [24%]). Some patients required addi-
tional courses of treatment, but all were ﬁnally cured (excluding
the 6 lost to follow-up). Of 10 evaluable immunosuppressed pa-
tients, 3 were treated locally and cured, whereas 3 of 7 patients
receiving systemic treatment were cured.
Adverse Events
Of the 50 patients receiving systemic therapy, 15 (30%) experi-
enced at least 1 systemic adverse event (AE). All systemic AEs
occurred in patients receiving systemic antimony (7 of 14), sys-
temic liposomal amphotericin B (7 of 21), or miltefosine (1 of
1; Table 2). The grading according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
deﬁnition (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_
2010-06-14_QuickReference_5×7.pdf) was 1 (mild) = 5 patients;
Table 1. Main Characteristics and Initial Outcome of 109 Evaluable Patients
Situation 1 (n = 25) Situation 2 (n = 47) Situation 3 (n = 37)
Systemic Therapy
Characteristic and Outcome Simple Wound Care
Cryotherapy Plus
Intralesional Antimony
(Sb, L-AmB, Pentamidine,
Miltefosine)
Patients
Age, y, median (IQR) 30 (8–52) 44 (12–57) 51 (34–61)
Sex, M/F, No. 11/14 23/24 27/10
Diabetes, cardiac, or renal history 3 (12) 6 (13) 9 (24)
Immunocompromised patients 0 (0) 3 (6) 7 (19)
Infecting Leishmania species, suspected or proven
L. major 20 (80) 28 (60) 13 (35)
L. mexicana 1 (4) 1 (2) . . .
L. tropica . . . 5 (11) 1 (3)
L. aethiopica . . . 2 (4) . . .
L. infantum/L. donovani 2 (8) 9 (19) 8 (22)
L. braziliensis . . . 2 (4) 6 (16)
L. guyanensis/L. panamensis 2 (8) . . . 9 (24)
Lesions
No., median (IQR) 2 (1–4) 2 (1–4.5) 2 (1–4)
Longest diameter, mm, median (IQR) 15 (14–24) 20 (10–30) 27.5 (20–50)
Outcome
Cure 23 (92) 37 (79) 22 (60)
Failure 2 (8) 5 (11) 13 (35)
Relapse 0 (0) 2 (4) 2 (5)
Lost to follow-up 0 (0) 3 (6) 0 (0)
Systemic adverse events 0 (0) 0 (0) 12 (32)
Local adverse events 0 (0) 3 (6) 0 (0)
Data are No. (%) unless otherwise specified.
Abbreviations: IQR, interquartile range; L-AmB, liposomal amphotericin B; Sb, pentavalent antimony.
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Table 2. Main Features of Reported Adverse Events in the 135 Patients Involved in the Centralized Referral Treatment Program
Age/Sex
First-Line
Drug
AEs in Patients Receiving
Either Systemic or Local
Therapy as Initial or
Second-Line Treatment Gradea (CTCAE)b Preexisting Morbidity Rx Stopped Final Outcome of AE and CL
51/F L-AmB Acute renal failure 2 Anti–TNF-α immunosuppressive
therapy for ankylosing
spondylitis
Daily dose reduction No sequelae
Healing
57/M L-AmB Raised serum creatinine 1 HABP Yes No sequelae
Healing after oral miltefosine ×15 d
60/F L-AmB Raised serum creatinine 1 Diabetes, chronic active hepatitis
C
Yes No sequelae
Healing after 2 d course of L-AmB
63/M L-AmB Acute renal failure 2 Hypertensive cardiopathy
immunosuppressive therapy:
alkylating agent for lymphoma
Yes No sequelae
Healing
80/M L-AmB Congestive cardiac failure 2 History of heart and kidney
disease
Yes No sequelae
Healing after oral miltefosine
83/M L-AmB Raised serum creatinine 1 HABP Infusions every 3 days No sequelae
Healing after oral miltefosine
85/M L-AmB Acute renal failure 2 No No sequelae
Relapse healing after Cryo + IlSb
21/M MA Fever 1 None No No sequelae
Healing
42/M MA Raised liver enzymes (AST) 2 Positive serology AgHBs Yes No sequelae
Healing
45/M MA DRESSc Hypereosinophilia,
fever, paresthesia, rash
2 Yes Paresthesia for 6 mo
Healing
50/M MA Dyspnea, thoracic
oppression, myalgia,
raised lipase,
thrombocytopenia,
lymphopenia
2 Yes No sequelae
Healing
57/M MA Raised serum amylase and
lipase
4 Diabetes, hypertensive
cardiopathy
Yes No sequelae
Healing
71/M MA Raised serum amylase and
lipase
4 HABP Yes No sequelae
Healing
74/M MA Inflammatory syndrome,
macrocytic anemia, and
lymphopenia
2 Yes No sequelae
Healing
61/M Miltefosine Raised liver enzymes (AST) 1 Immunosuppressive therapy:
MTX and corticoids for
rheumatoid polyarthritis
Yes No sequelae
Relapse then lost to follow-up
376
•
C
ID
2013:57
(1
A
u
gust)
•
M
orizotetal
2 (moderate) = 8 patients; 4 (life threatening) = 2 patients. In 14
patients receiving systemic antimony, the median age was 50.7
years (IQR, 44.1–55.7 years) for those experiencing a systemic
AE, and 41.4 years (IQR, 34.6–47.4 years) for those without
systemic AE. Only 3 (6%) AEs (all mild) were reported in the
47 patients receiving Cryo + IlSb.
DISCUSSION
Our analysis, based on a nationwide, centralized, referral treat-
ment program, shows that a majority of travelers with CL can
be treated locally rather than systemically, and that this guide-
line-based approach is generally associated with a positive
outcome. More than half of the patients (62%) were indeed ini-
tially managed without systemic therapy, either by simple
wound care (19%), by Cryo + IlSb (41%), or by topical therapy
with ointments. Cure rates at days 42–60 in patients with com-
plete charts were 92% for simple wound care and 79% for
Cryo + IlSb. Relatively few patients had been infected in the
NewWorld (21%), and 56% of all patients were infected with L.
major. Our analysis was thus partially skewed toward a simple
wound care approach. Yet, the high proportion of positive out-
comes in this subgroup (92%) suggests that the criteria used to
recommend this option accurately predict patients who will
self-cure; this furthermore included several patients who were
not infected with L. major. When appropriately selected, and
informed about the lack of risk for themselves and others, a
vast majority of patients followed this approach until cure. Pre-
dictably, no AEs were reported in this group.
Conversely, AEs occurred in 15 (30%) of the 50 patients re-
ceiving systemic therapy. None of these AEs resulted in long-
term sequelae but treatment was prematurely interrupted in 11
of these patients. We emphasize that these decisions to discon-
tinue treatment were based on close monitoring of clinical and
laboratory parameters. This evokes the question of what would
have been the outcome if laboratory parameters had been less
easily accessible, a frequent situation in several CL-endemic
countries where systemic antimony, and possibly other system-
ic regimens, are administered with no systematic follow-up of
laboratory ﬁndings. In a recent analysis of systemic antimony
toxicity in 67 travelers without preexisting morbidity, close
follow-up of laboratory data was key for a timely suspension of
treatment in 6 patients [38]. Recent observations in Tunisia
suggest that antimony-induced severe adverse events affecting
the kidney or liver are not exceptional [39]. Taken together,
these observations reinforce the current assertion that the
beneﬁt-risk ratio of systemic anti-leishmanial therapy for CL
requires cautious evaluation in the general population of pa-
tients. In 14 patients receiving systemic antimony, the median
age was 50.7 years (IQR, 44.1–55.7 years) for those experienc-
ing a systemic AE, and 41.4 years (IQR, 34.6–47.4 years) forTa
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those without systemic AE. The risk of mortality under system-
ic antimony for visceral leishmaniasis is signiﬁcantly greater in
patients older than 45 years [40, 41]. Although based on a
limited number of patients, our observation suggests that older
age may also be associated with an increased risk of antimony-
induced systemic AE in patients with CL, either directly or as a
surrogate for preexisting comorbidities. Whereas the popula-
tion of volunteers in many clinical trials of systemic antimony
has been markedly biased toward young adult males without
preexisting morbidity [32, 42–45], our population encompassed
a broad spectrum of clinical situations, including prior anti-
leishmanial therapy (24%), preexisting comorbidities (16%),
and immunosuppression (9%; Supplementary Table 1). Our
data also suggest that in older patients with frequent comorbid-
ities and/or large lesions (situation 3 in the algorithm), infec-
tion with all species (including L. major) may be difﬁcult to
cure, thus justifying a speciﬁc management and adapted re-
search strategies. International initiatives (eg, LeishMan Euro-
pean network, http://www.tropnet.net/index.php?id=103) will
allow for a powerful determination of factors associated with
positive outcome and help further improve treatment algo-
rithms and recommendations.
Limiting the proportion of patients receiving systemic
therapy is likely a simple way of reducing therapeutic risk. AEs
were infrequent in the 47 patients receiving Cryo + IlSb; those
that did occur were mild. Although the proportion of patients
selected for local therapy (including simple wound care) may
be smaller in countries/areas where L. major is less prevalent,
we nonetheless believe that the general stepwise approach ana-
lyzed here will be useful elsewhere. Indeed it provides a simple,
harmonized strategy for general treatment decisions in CL,
based on a robust equilibrium between the beneﬁts and the
risks of available options. More than two-thirds of the patients
infected with L. infantum, L. aethiopica, or L. tropica were
managed without systemic therapy, and the cure rate in this
group was similar to that of the L. major–infected patients
(83% vs 82%). Conﬁrmation of this ﬁnding in larger cohorts of
patients is needed. Although traditionally limited to systemic
therapy [32], recommendations and investigations for the treat-
ment of NewWorld cutaneous leishmaniasis have progressively
included local therapy [26, 46–48]. This decision is largely
based on a detailed analysis of the relatively small risk of evolu-
tion to mucocutaneous leishmaniasis outside of Bolivia [49], and
on the rise of new options to treat mucocutaneous leishmaniasis
if it occurs [12, 15, 16, 50]. Four of the 19 patients (21%) with
suspected or proven L. braziliensis or L. panamensis/guyanensis
infection were treated and cured without systemic therapy.
Although the stepwise approach validated here optimizes the
use of the existing armamentarium, the improvement of this
latter remains an essential goal. Current treatment guidelines
display a strong synergism with the emergence of a new
formulation of topical aminoglycosides for the treatment of L.
major CL [28, 51].When available, this third-generation topical
aminoglycoside ointment will replace simple wound care and
Cryo + IlSb, thus resulting in further simpliﬁcation of treatment
strategies. In addition, because it is simpler to apply a cream
than to perform Cryo + IlSb, the proportion of patients treated
topically will surely grow compared to that of patients receiving
systemic treatments. Only lesions of eyelids, lips, genitalia, and
mucosae are ineligible for topical therapy, that is, 10% of
lesions in our experience (Figure 3). A vast majority of patients
will thus beneﬁt from this inexpensive approach. Further evalu-
ations of topical aminoglycoside formulations in CL due to
other Old World and New World species are ongoing or
planned [51].
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